MRES OTC
Institute of Biomedical Research Corp.
1W: -20.4%
1M: -56.2%
3M: +86.2%
YTD: -37.5%
1Y: -71.8%
3Y: -93.1%
5Y: -89.5%
$0.00
-0.00 (-14.63%)
Weekly Expected Move ±26.6%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$49K
+9.8% ▲
Gross Profit
$21K
+150.3% ▲
Operating Income
-$757K
+57.9% ▲
Net Income
-$633K
-147.6% ▼
EPS (Diluted)
$-0.00
-133.3% ▼
EBITDA
-$724K
-152.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $29K | $45K | $49K |
| YoY Growth | +0.0% | +0.0% | +0.0% | +53.1% | +9.8% |
| Cost of Revenue | $0 | $0 | $21K | $37K | $28K |
| Gross Profit | $0 | $0 | $9K | $9K | $21K |
| Gross Margin | — | — | 29.5% | 19.0% | 43.2% |
| R&D Expenses | $0 | $0 | $4K | $209K | -$110K |
| SG&A Expenses | $44K | $167K | $728K | $2M | $888K |
| Operating Expenses | $44K | $167K | $733K | $2M | $778K |
| Operating Income | -$44K | -$167K | -$724K | -$2M | -$757K |
| Operating Margin | — | — | -2458.5% | -3985.0% | -1528.7% |
| Interest Expense | $0 | $0 | $49K | $37K | $15K |
| Income Before Tax | -$44K | -$167K | -$433K | $1M | -$740K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$44K | -$167K | -$433K | $1M | -$633K |
| Net Margin | — | — | -1472.0% | 2950.3% | -1278.6% |
| EPS (Diluted) | $0.00 | $-0.00 | $-0.00 | $0.00 | $-0.00 |
| EBITDA | -$44K | -$167K | -$384K | $1M | -$724K |
| Shares Outstanding | 916M | 916M | 1.45B | 2.37B | 2.66B |